Dashboard
Manage Tickers

RPTXRepare Therapeutics Inc.

Nasdaq reparerx.com


$ 3.46 $ 0.10 (2.99 %)    

Friday, 03-May-2024 15:59:49 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 3.45
$ 3.51
$ 0.00 x 0
$ 0.00 x 0
$ 3.46 - $ 3.65
$ 2.98 - $ 13.85
173,798
na
145.22M
$ 0.84
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-28-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-09-2023 06-30-2023 10-Q
4 05-09-2023 03-31-2023 10-Q
5 02-28-2023 12-31-2022 10-K
6 11-09-2022 09-30-2022 10-Q
7 08-04-2022 06-30-2022 10-Q
8 05-05-2022 03-31-2022 10-Q
9 03-01-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-12-2021 06-30-2021 10-Q
12 05-13-2021 03-31-2021 10-Q
13 03-04-2021 12-31-2020 10-K
14 11-12-2020 09-30-2020 10-Q
15 08-13-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

repare-therapeutics-and-debiopharm-have-dosed-the-first-patient-in-phase-11b-mythic-trial-investigating-lunresertib-in-combination-with-debio-0123
Repare Therapeutics And Debiopharm Have Do...
04/30/2024 11:11:38

roches-lymphoma-drug-with-chemo-extends-survival-in-pretreated-patients
Roche's Lymphoma Drug With Chemo Extends S...
04/15/2024 12:56:25

Roche study results show prolonged survival in R/R diffuse large B-cell lymphoma patients treated with Columvi (glofitamab) + G...

hc-wainwright--co-reiterates-buy-on-repare-therapeutics-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Repa...
03/08/2024 12:03:44

HC Wainwright & Co. analyst Robert Burns reiterates Repare Therapeutics (NASDAQ:RPTX) with a Buy and maintains $10 price...

recap-repare-therapeutics-q4-earnings
Recap: Repare Therapeutics Q4 Earnings
02/28/2024 14:40:07

hc-wainwright--co-reiterates-buy-on-repare-therapeutics-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Repa...
02/21/2024 11:44:09

HC Wainwright & Co. analyst Robert Burns reiterates Repare Therapeutics (NASDAQ:RPTX) with a Buy and maintains $10 price...

repare-therapeutics-has-dosed-the-first-patient-in-phase-1--lions-trial-evaluating-rp-1664-for-the-monotherapy-treatment-of-adult-and-adolescent-patients-enriched-for-trim37-high-solid-tumors
Repare Therapeutics Has Dosed The First Pa...
02/15/2024 12:16:47

hc-wainwright--co-maintains-buy-on-repare-therapeutics-lowers-price-target-to-10
HC Wainwright & Co. Maintains Buy on Repar...
02/14/2024 11:47:24

HC Wainwright & Co. analyst Robert Burns maintains Repare Therapeutics (NASDAQ:RPTX) with a Buy and lowers the price tar...

roche-terminates-cancer-drug-pact-with-repare-therapeutics-its-second-walkout-within-a-month
Roche Terminates Cancer Drug Pact With Rep...
02/13/2024 13:43:35

Repare Therapeutics regains global rights to camonsertib (RP-3500) after terminating collaboration with Roche. $40M milestone a...

Core News & Articles
Repare Therapeutics To Regain Global Devel...
02/12/2024 21:10:01

Roche notified Repare that, effective May 7, 2024, it is terminating its worldwide license and collaboration agreement for the ...

Core News & Articles
Repare Therapeutics Under Its Worldwide Li...
01/25/2024 12:05:43

repare-therapeutics-provides-corporate-update-and-highlights-anticipated-key-2024-milestones-ended-2023-with-approximately-223m-in-cash-cash-equivalents-and-marketable-securities-which-is-anticipated-to-fund-planned-operations-into-mid-2026
Repare Therapeutics Provides Corporate Upd...
01/08/2024 12:48:14

debiopharm-partners-with-repare-therapeutics-to-explore-synthetic-lethal-combination-of-pkmyt1-and-wee1-inhibition-in-cancer
Debiopharm Partners With Repare Therapeuti...
01/04/2024 21:11:39

Collaborative clinical study will investigate a novel combination of Debio 0123, Debiopharm's potent, brain penetrant inhib...

hc-wainwright--co-reiterates-buy-on-repare-therapeutics-maintains-25-price-target
HC Wainwright & Co. Reiterates Buy on Repa...
11/20/2023 11:40:35

HC Wainwright & Co. analyst Robert Burns reiterates Repare Therapeutics (NASDAQ:RPTX) with a Buy and maintains $25 price...

recap-repare-therapeutics-q3-earnings
Recap: Repare Therapeutics Q3 Earnings
11/09/2023 12:55:06

repare-therapeutics-q3-eps-045-beats-086-estimate-sales-216m-miss-631m-estimate
Repare Therapeutics Q3 EPS $(0.45) Beats $...
11/09/2023 12:47:46

Repare Therapeutics (NASDAQ:RPTX) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $...

Core News & Articles
$2.8M Bet On Repare Therapeutics? Check Ou...
11/06/2023 13:24:14

The Dow Jones closed higher by over 200 points on Friday. When insiders purchase or sell shares, it indicates their confidence ...

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
11/06/2023 13:06:45

repare-therapeutics-shares-higher-premarket-10-owner-mark-lampert-reported-purchase-of-783709-shares--avg-price-of-360share-in-form-4-filing-on-friday
Repare Therapeutics Shares Higher Premarke...
11/06/2023 10:01:24

piper-sandler-maintains-overweight-on-repare-therapeutics-lowers-price-target-to-25
Piper Sandler Maintains Overweight on Repa...
10/16/2023 17:37:25

Piper Sandler analyst Joseph Catanzaro maintains Repare Therapeutics (NASDAQ:RPTX) with a Overweight and lowers the price ta...

repare-therapeutics-announces-initial-data-from-phase-1-mythic-clinical-trial-evaluating-lunresertib-alone-and-in-combination-with-camonsertib
Repare Therapeutics Announces Initial Data...
10/13/2023 13:41:51

Lunresertib + camonsertib combination demonstrated clear signals of anti-tumor activity across multiple tumor types and all sel...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION